Drugs Made In America Acquisition II Corp. (DMII) Non-Current Assets (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Non-Current Assets for 3 consecutive years, with $513.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $513.9 million in Q2 2026; TTM through Jun 2026 was $513.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $504.9 million, up 643545.94% from the prior year.
• Non-Current Assets was $513.9 million for Q2 2026 at Drugs Made In America Acquisition, up from $504.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $513.9 million in Q2 2026 and troughed at $78449.0 in Q4 2024.
• A 3-year average of $379.8 million and a median of $502.5 million in 2025 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 643545.94% in 2025, down 643545.94% in 2025.
• Over 3 years, Non-Current Assets stood at $78449.0 in 2024, then jumped by 643545.94% to $504.9 million in 2025, then rose by 1.77% to $513.9 million in 2026.
• The last three Non-Current Assets figures came in at $513.9 million (Q2 2026), $504.9 million (Q4 2025), and $500.1 million (Q3 2025), per Business Quant data.